Pulse Biosciences, Inc

PLSE Healthcare Medical Instruments & Supplies

Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022. In the quarter to June 2026, revenue grew 4,922.2%, EPS fell 28.6% and free cash flow fell 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

44.27 1.32 −2.90%
Market cap
$3.3B
P/E
0.0×
Fwd P/E
−19.0×
Dividend yield
—
F-score
n/a
Altman Z
31.41
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(86.99%) (74.45%) (80.72%) (78.49%)
ROA
(74.06%) (64.12%) (69.36%) (67.90%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(84.43%) (95.08%) (119.59%) (83.58%)
Average Days of Receivables
6.97 165.03 77.23 37.58
Free Cash Flow per Share
(0.72) (0.81) (0.82) (0.89)
Free Cash Flow
(48.77) (54.44) (55.50) (61.39)
Other line items

Show all line items

Columns are period end dates